Mortality Reduction Associated with Coexistent Antithrombotic Use in Nursing Home Residents with COVID-19

Long-term care facilities, particularly skilled nursing facilities (SNFs), have felt the impact of the COVID-19 pandemic, with high mortality rates observed in residents. SNF residents comprise less than 1% of the US population,1 however, this population accounted for over 31% of COVID-19 deaths in the United States through June 2021.2 Following the noted increased risk of venous thromboembolism observed in patients with COVID-19,3,4 investigations have demonstrated increased survival in noncritically ill hospitalized individuals treated with heparin.